ProCE Banner Activity

PRIME Phase I/II Trial of P-BCMA-101: Novel CAR T-Cell Therapy in R/R Multiple Myeloma

Slideset Download
Conference Coverage
Preliminary data from phase I/II study on novel CAR T-cell therapy, P-BCMA-101, suggest safe and effective treatment for relapsed and refractory multiple myeloma.

Released: December 07, 2020

Expiration: December 06, 2021

No longer available for credit.
Begin Activity

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

AstraZeneca

Bristol Myers Squibb

Epizyme, Inc.

GlaxoSmithKline

Incyte Corporation

Janssen Biotech

Karyopharm Therapeutics Inc.

Novartis

PharmaEssentia Corp

Seagen

Takeda Oncology